The Library
Association of cerebrospinal fluid neurofilament heavy protein levels with clinical progression in patients with Parkinson disease
Tools
Wang, Linbo, Zhang, Wei, Liu, Fengtao, Mao, Chengjie, Liu, Chun-Feng, Cheng, Wei and Feng, Jianfeng (2022) Association of cerebrospinal fluid neurofilament heavy protein levels with clinical progression in patients with Parkinson disease. JAMA Network Open, 5 (7). e2223821. doi:10.1001/jamanetworkopen.2022.23821 ISSN 2574-3805.
|
PDF
WRAP-Association-cerebrospinal-fluid-neurofilament-heavy-protein-levels-22.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1337Kb) | Preview |
Official URL: https://doi.org/10.1001/jamanetworkopen.2022.23821
Abstract
Importance Neurofilament light in biofluids has been associated with progression of Parkinson disease (PD), but the association between neurofilament heavy (NfH) and progression of PD has not been investigated.
Objective To evaluate the associations of cerebrospinal fluid (CSF) NfH (cNfH) levels and motor and cognitive progression in PD.
Design, Setting, and Participants This cohort study used data from the Parkinson Progression Marker Initiative ranging from June 2010 to November 2018. Participants were recruited from 24 participating sites worldwide (United States, Europe, and Australia). Data were analyzed from October 20 to December 18, 2021.
Exposures Concentrations of NfH in CSF.
Main Outcomes and Measures The primary outcomes were Movement Disorder Society–sponsored revisions of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III; scores range from 0 to 132, with higher scores indicating worse motor function, and Montreal Cognitive Assessment (MoCA); scores range from 0 to 30, with higher scores indicating better cognitive function. The associations of cNfH levels and longitudinal change in MDS-UPDRS-Part-III and MoCA were examined using linear mixed-effects models with PD duration as the time scale. Partial correlation analysis was conducted to examine the associations of cNfH levels and α-synuclein, amyloid-β 1-42 (Aβ42), phosphorylated tau at threonine 181 position (P-tau), and total tau (T-tau) levels in CSF.
Results A total of 404 patients with PD (mean [SD] age, 61.7 [9.7] years; 263 were men [65.1%]; within 2 years of diagnosis; Hoehn and Yahr <3) were included. Higher baseline cNfH levels were associated with greater increases in MDS-UPDRS Part-III (β = 0.39; 95% CI, 0.12-0.66; P = .003) and faster decreases in MoCA (β = −0.18; CI, −0.24 to −0.11; P < .001). Levels of cNfH were correlated with CSF levels of α-synuclein (Spearman r = 0.25; 95% CI, 0.15-0.34; P < .001), Aβ42 (Spearman r = 0.18; 95% CI, 0.08-0.27; P < .001), P-tau (Spearman r = 0.25; 95% CI, 0.15-0.35; P < .001), and T-tau (Spearman r = 0.31; 95% CI, 0.21-0.40; P < .001) at baseline.
Conclusions and Relevance Higher baseline cNfH levels were associated with faster motor and cognitive progression. This finding suggests that cNfH may be of some value for stratifying patients with PD who have different progression rates.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Science > Computer Science | ||||||
SWORD Depositor: | Library Publications Router | ||||||
Journal or Publication Title: | JAMA Network Open | ||||||
Publisher: | American Medical Association (AMA) | ||||||
ISSN: | 2574-3805 | ||||||
Official Date: | 26 July 2022 | ||||||
Dates: |
|
||||||
Volume: | 5 | ||||||
Number: | 7 | ||||||
Article Number: | e2223821 | ||||||
DOI: | 10.1001/jamanetworkopen.2022.23821 | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||
Date of first compliant deposit: | 17 August 2022 | ||||||
Date of first compliant Open Access: | 17 August 2022 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year